First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

Riccardo Giampieri,Marco Puzzoni,Bruno Daniele,Daris Ferrari,Sara Lonardi,Alberto Zaniboni,Luigi Cavanna,Gerardo Rosati,Nicoletta Pella,Maria Giulia Zampino,Pietro Sozzi,Domenico Germano,Vittorina Zagonel,Carla Codecà,Michela Libertini,Roberto Labianca,Stefano Cascinu,Mario Scartozzi

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

2017

Riccardo Giampieri
Marco Puzzoni
Bruno Daniele
Daris Ferrari
Sara Lonardi
Alberto Zaniboni
Luigi Cavanna
Gerardo Rosati
Nicoletta Pella
Maria Giulia Zampino
Pietro Sozzi
Domenico Germano
Vittorina Zagonel
Carla Codecà
Michela Libertini
Roberto Labianca
Stefano Cascinu
Mario Scartozzi

First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial

Keywords:

Medicine
Pathology
Immunology
FOLFIRI
Bevacizumab
Colorectal cancer
Clinical endpoint
Prospective cohort study
Fluorouracil
Basal (phylogenetics)
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations